Health insurance won’t pay for experimental drugs, so there is not much incentive for drug comapanies to support the dual track approach.
Yes, apologies for my mistake.
Health insurance won’t pay for experimental drugs, so there is not much incentive for drug comapanies to support the dual track approach.
Yes, apologies for my mistake.